Eledon Pharmaceuticals
ELDN
13 hedge funds and large institutions have $2.1M invested in Eledon Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
30% more funds holding
Funds holding: 10 → 13 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.22% less ownership
Funds ownership: 2.08% → 1.86% (-0.22%)
25% less capital invested
Capital invested by funds: $2.82M → $2.1M (-$717K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$343K |
| 2 |
Rockefeller Capital Management
New York
|
+$15.9K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$2.63K |
| 4 |
Renaissance Technologies
New York
|
+$841 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$134 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$76.5K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| 4 |
BlackRock
New York
|
-$640 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $1.24M | – | – | – |
|
|
6CM
2
683 Capital Management
New York
| $369K | +$343K | +35,900 | +215% |
|
|
BI
3
BVF Inc
San Francisco,
California
| $267K | -$76.5K | -8,004 | -17% |
|
|
4
Renaissance Technologies
New York
| $178K | +$841 | +88 | +0.3% |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $15K | – | – | – |
|
|
6
BlackRock
New York
| $12K | -$640 | -67 | -4% |
|
|
7
Rockefeller Capital Management
New York
| $12K | +$15.9K | +1,667 | New |
|
8
Geode Capital Management
Boston,
Massachusetts
| $4K | – | – | – |
|
|
9
Victory Capital Management
San Antonio,
Texas
| $2K | +$2.63K | +275 | New |
|
|
10
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -226 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$2K | -206 | Closed |
|
12
Wells Fargo
San Francisco,
California
| – | +$38 | +4 | New |
|
13
JP Morgan Chase
New York
| – | +$57 | +6 | New |
|
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$134 | +14 | New |
|
ELDN Hedge Fund Activity: Q1 2020 in Review
13 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2020, worth a combined $2.1M — down 25% from $2.82M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ELDN positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $343K. The largest seller was BVF Inc, cutting an estimated $76.5K.
- 13 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2020, up from 10 in Q4 2019.
- Funds reported $2.1M of Eledon Pharmaceuticals stock for Q1 2020, down 25% quarter-over-quarter.
- 5 funds opened new Eledon Pharmaceuticals positions in Q1 2020 and 2 closed out, a net change of +3 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2020 was 683 Capital Management, an estimated $343K added.
- The largest Eledon Pharmaceuticals seller in Q1 2020 was BVF Inc, an estimated $76.5K sold.
Based on aggregated 13F filings for Q1 2020.